Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non–small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung). Issue 2 (15th February 2022)

• Record Type: Journal Article
• Authors: Sebastian, Martin; Gröschel, Andreas; Gütz, Sylvia; Schulz, Holger; Müller-Huesmann, Harald; Liersch, Rüdiger; von der Heyde, Eyck; Wiegand, Jörg; Ukena, Dieter; Bargon, Joachim; Schütte, Wolfgang; Riera-Knorrenschild, Jorge; Fischer, Jürgen R.; Griesinger, Frank; Allan, Victoria; Waldenberger, Daniela; Schumann, Christian
• Is Part Of: Journal of immunotherapy. Volume 45:Issue 2(2022)
• Page Start: 89
• Page End: 99
• Publication Date: 2022-02-15
• Subjects: NSCLC -- nivolumab -- real-world -- noninterventional; Immunotherapy -- Periodicals; Immunotherapy -- Periodicals; Neoplasms -- therapy -- Periodicals; Electronic journals; Electronic journals; 615.37
• DOI: 10.1097/CJI.0000000000000397
• Languages: English
• ISSNs: 1524-9557

Abstract

Abstract : Supplemental Digital Content is available in the text. Abstract : Nivolumab was the first immune checkpoint inhibitor approved for use in advanced non–small cell lung cancer (NSCLC). This noninterventional, prospective cohort study investigates real-world effectiveness of nivolumab in pretreated NSCLC patients in Germany (Enlarge-Lung/CA209-580). Patients with squamous (SQ) or nonsquamous (NSQ) NSCLC previously treated for locally advanced or metastatic (stage IIIB/IV) disease received nivolumab according to the current Summary of Product Characteristics. Overall survival (OS) was the primary endpoint. Of 907 patients enrolled, 660 patients who were followed for at least 12 months across 79 study centers in Germany, were analyzed. Median OS was 11.2 months [95% confidence interval (CI), 9.1–12.9]; outcomes for the 418 patients with NSQ histology [13.1 mo (95% CI, 10.6-15.6)] were more favorable than outcomes for the 242 patients with SQ histology [8.9 mo (95% CI, 6.4-11.3)]. Patients' age, presence of distant or brain metastases, or line of therapy did not affect outcomes; however, patients with poor performance status (ECOG-PS ≥2, n=80) had shorter median OS [4.7 mo (95% CI, 3.1–5.4)]. This study represents one of the largest real-world cohorts providing outcomes of nivolumab in pretreated NSCLC. The results match well with the published evidence from pivotal clinical trials and demonstrate clinical effectiveness of nivolumab in advanced NSCLC.